Nicergoline CAS 27848-84-6 1-methyl-lumilysergol8-(5-bromonicotinate)10-methylether

Model: MOS 17
Place of Origin: Zhejiang,China (Mainland)
Name: Nicergoline
CAS: 27848-84-6
Molecular Formula: C24H26BrN3O3
Molecular Weight: 484.39
Content: 98%min
Synonyms 1: fi6714
Synonyms 2: 1-methyl-lumilysergol8-(5-bromonicotinate)10-methylether
storage temp.: 2-8°C
Water Solubility: Soluble in alcohol, chloroform, and acetone. Insoluble in water.


skype basketAdd to Basket  Edit

Share |

Product Description

Payment & Shipping Terms Supply Capacity
Trade Term:FOB,CIF,DDPProduction Capacity:200KG/MONTH
Payment Terms:L/C, T/T, WUPacking:As per request of...
Min. Order:1 KilogramDelivery Date:within 7 days
Means of Transport:Ocean, Air, Land

Nicergoline CAS 27848-84-6 1-methyl-lumilysergol8-(5-bromonicotinate)10-methylether

Nicergoline Usage And Synthesis




Biological Activity

α -adrenergic, vasodilator. Cognitive enhancer.


Nicergoline CAS 27848-84-6 1-methyl-lumilysergol8-(5-bromonicotinate)10-methylether


Nicergoline (INN, marketed under the trade name Sermion) is an ergot derivative used to treat senile dementia and other disorders with vascularorigins. It decreases vascular resistance and increases arterial blood flow in the brain, improving the utilization of oxygen and glucose by brain cells. It has similar vasoactive properties in other areas of the body, particularly the lungs.

It is used for vascular disorders such as cerebral thrombosis and atherosclerosis, arterial blockages in the limbs, Raynaud's disease, vascularmigraines, and retinopathy.

Nicergoline has been registered in over fifty countries and has been used for more than three decades for the treatment of cognitive, affective, and behavioral disorders of older people.

Persons suffering from acute bleeding, myocardial infarction (heart conditions), hypertension, bradycardia or using alpha or beta receptor agonists should consult with their physician before use. Although toxicology studies have not shown nicergoline to have any teratogenic effect, the use of this medicine during pregnancy should be limited to those cases where it is absolutely necessary.

On 28 June 2013 the European Medicines Agency recommended restricting the use of medicines containing ergot derivatives, including nicergoline. They stated that "these medicines should no longer be used to treat several conditions involving blood circulation problems or problems with memory and sensation, or to prevent migraine headaches, since the risks are greater than the benefits in these indications. This is based on a review of data showing an increased risk of fibrosis (formation of excess connective tissue that can damage organs and body structures) and ergotism (symptoms of ergot poisoning, such as spasms and obstructed blood circulation) with these medicines."

Nicergoline is considered unsafe in porphyria.

The side effects of nicergoline are usually limited to nausea, hot flushes, mild gastric upset, hypotension and dizziness.At high dosagesbradycardia, increased appetite, agitation, diarrhea and perspiration have been known to occur. A single case of acute interstitial nephritis has been reported.

Category: Other Pharmaceutical API

Related Category: Antineoplastic Drugs API  Heart And Cerebral Vessels API  Hot anti-cancer medicines  Pharmaceutical Intermediates  Customized Pharmaceutical API 

Offline Showroom in USA
QR Code